PressFebruary 3, 2021 Champignon Brands : New Rapid mood Screener (RMS) Screens for Manic Symptoms and Bipolar I Disorder Features to Address Unmet Clinical Need
PressFebruary 2, 2021 MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
PressFebruary 1, 2021 PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
PressJanuary 29, 2021 Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
PressJanuary 26, 2021 Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US
PressJanuary 25, 2021 Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression
PressJanuary 20, 2021 MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
PressJanuary 19, 2021 Better Plant Affiliate NeonMind Lists on the Frankfurt Stock Exchange (FSE: 6UF)
PressJanuary 15, 2021 Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
PressJanuary 14, 2021 MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
PressJanuary 12, 2021 MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
PressJanuary 11, 2021 Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics
PressJanuary 8, 2021 COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
PressJanuary 7, 2021 MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand
PressJanuary 6, 2021 Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
